Vyome Biosciences

Vyome Therapeutics Inc. is an innovation-driven company with a vision to develop novel therapeutics targeting resistant acne and other opportunistic pathogens through unique antibiotic development that delays the emergence of resistance. Members of Vyome’s management team are leaders in this field, possessing deep expertise, strong capabilities, and a proven track record of successfully launching over 50 products and building visionary companies in dermatology and other life sciences sectors. Vyome's development platform has been fully de-risked. Vyome boasts a rich pipeline of IP-based products for multiple indications. The lead molecule (VB 1953), which addresses significant unmet needs in the prescription market for resistant acne, is currently being evaluated in clinical trials in the United States. Vyome has state-of-the-art infrastructure to support all its research and lab development activities, including well-established formulation, analytical, chemistry, biology, molecular biology, clinical, and regulatory departments. Vyome's infrastructure and team enable the company to conceptualize, develop ideas, and commercialize them.